Liquid oral formulations for sildenafil
US12186321B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 4, 2024 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Apr 4, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.